Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes
NCT03496298Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 28
01
Overview
A Phase 3 trial of efpeglenatide in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Started Apr 2018; status: terminated.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03496298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496298.